Walder Wyss Attorneys at Law | Oversubscribed USD 152 Million Series…
Vaderis Therapeutics secured a USD 152 million Series B funding to advance its global Phase 3 HEROIC trial of engasertib (VAD044) for hereditary hemorrhagic telangiectasia (HHT).
Sponsored
Tokenize your real-world asset with Curio
Vaderis Therapeutics secured a USD 152 million Series B funding to advance its global Phase 3 HEROIC trial of engasertib (VAD044) for hereditary hemorrhagic telangiectasia (HHT).
The announcement centers on a corporate merger plan under Swiss Digital Home AG to unify houzy and myky and their platforms, with no specific details provided about funding, tokenization, allocation, or hiring signals.
Walder Wyss states that UBS Switzerland AG led the acquisition financing for EGS Beteiligungen AG’s purchase of Netcloud AG, with Walder Wyss coordinating and coordinating the entire banking syndicate as mandated lead arranger/agent.
Healthcare Holding Schweiz AG secured a new syndicated credit facilities agreement with UBS and additional lenders (Liechtensteinische Landesbank, Bank CIC (Schweiz), Zuger Kantonalbank) to fund its operations, signaling ongoing financing and expansion in its role as Switzerland’s largest independent Medtech distributor.
Daily 5 RWA signals